# OnCo record paper-topalian-anti-pd1-nejm-2012 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-topalian-anti-pd1-nejm-2012/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-topalian-anti-pd1-nejm-2012" ;
  schema:name "Topalian 2012: the first large trial of a PD-1 antibody shows durable responses across melanoma, lung and kidney cancer"@en ;
  schema:description "Nivolumab shrank tumours in roughly a fifth to a quarter of patients with three different advanced cancers, with responses that lasted more than a year and a hint that PD-L1 on the tumour predicted benefit."@en ;
  schema:url <https://onco.cc/key-papers/paper-topalian-anti-pd1-nejm-2012/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:citation <https://doi.org/10.1056/NEJMoa1200690>, <https://doi.org/10.1056/NEJMoa1200694> ;
  schema:sameAs <https://doi.org/10.1056/NEJMoa1200690> ;
  schema:datePublished "2012"^^xsd:gYear ;
  schema:author "Topalian SL, Hodi FS, Brahmer JR, et al." ;
  onco:related <https://onco.cc/key-papers/paper-hodi-ipilimumab-melanoma-nejm-2010/>, <https://onco.cc/pathways/pd1-checkpoint/>, <https://onco.cc/roadmaps/lung-cancer-evidence-roadmap/>, <https://onco.cc/key-papers/paper-herbst-impower110-atezolizumab-pd-l1-nejm-2020/> ;
  onco:cancers <https://onco.cc/cancers/melanoma/>, <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/lung-cancer/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:targets <https://onco.cc/targets/pd1/> ;
  onco:drugs <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/atezolizumab/> ;
  onco:companies <https://onco.cc/companies/bms/> ;
  onco:terms <https://onco.cc/terms/irae/>, <https://onco.cc/terms/orr/> ;
  onco:people <https://onco.cc/people/suzanne-topalian/>, <https://onco.cc/people/julie-brahmer/>, <https://onco.cc/people/drew-pardoll/>, <https://onco.cc/people/f-stephen-hodi/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-biomarker-validation/>, <https://onco.cc/bottlenecks/b-immunotherapy-response/> ;
  onco:journals <https://onco.cc/journals/nejm/> .